Navigation Links
New Patent for Adipose Stem Cells Issued to VetStem Biopharma
Date:7/31/2018

Leading regenerative veterinary medicine company, VetStem Biopharma, has been issued a major patent that covers methods for extracting and using adipose tissue-derived stem cells to treat or prevent inflammation at the site of musculoskeletal injury in any mammal, including humans. While this patent covers Canada specifically, VetStem has been issued similar patents that cover the United States as well as the EU.

The new patent adds to VetStem’s patent portfolio that covers methods of using regenerative cells from adipose tissue in humans and animals. CEO and VetStem founder, Dr. Bob Harman, believes these patents are an important way to strengthen the company’s intellectual property in the rapidly developing field of regenerative medicine.

As the first company to provide adipose derived stem cell services to veterinarians in the United States and Canada, VetStem has quickly developed the market. With over 13,000 animals treated, Dr. Harman believes it is crucial to take appropriate actions to protect the market they are developing and to optimize the value of the company. Dr. Harman stated, “We have invested heavily in patent protection of our technology and we have engaged appropriate counsel to work with companies interested in licensing our technology for commercial use.”

As stem cell therapy becomes more widely recognized and utilized in both veterinary and human medicine, VetStem strives to stay at the forefront of the field. They continue to explore non-standard uses for stem cells such as organ failure and immune-mediated diseases. The VetStem R&D team are also in the process of developing an off-the-shelf “donor-derived” stem cell product for arthritis in canines and additional products for use in feline and equine disease therapy. VetStem has three Investigational New Animal Drug applications filed with the FDA.

About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 13,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The Company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at https://www.prweb.com/releases/new_patent_for_adipose_stem_cells_issued_to_vetstem_biopharma/prweb15661247.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. First-To-File Patent Law Is Now In Effect, But What Does it Mean?
2. APPLIED PHYSIOLOGY® Receives key US Patent Award for its Unique NAVIGATOR™ Technology
3. Synedgen Announces Issuance of Patent to Optimize Animal Health
4. Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438
5. Nutra Pharma Patent and Trademarks Published in India
6. Marrone Bio Innovations Files Patent for a Unique Bacillus Species
7. Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel
8. LamdaGen Corporation Announces Japan Patent Issuance for Enzymatic Diagnostic Assays on Plasmonic Nano-Sensors
9. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
10. DuPont Receives ‘Patents for Humanity’ Award for Groundbreaking Research to Improve Nutritional Profile of Staple Crop
11. Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2018)... Calif. (PRWEB) , ... September 29, 2018 , ... ... analytics product enabling mid-level and early-stage companies to access the power of influence ... make our solutions available to a broader market that didn’t necessarily have access ...
(Date:9/27/2018)... ROCHELLE, Va. (PRWEB) , ... September 26, 2018 ... ... announced today that Dr. B. Melina Cimler, a senior quality, regulatory, and in ... life science and FDA-regulated global diagnostic industry has joined the firm as an ...
(Date:9/27/2018)... ... September 26, 2018 , ... Nvision Biomedical ... Pedicle Screw System today at the North American Spine Society (NASS) Annual Meeting, ... Nvision focus Pedicle Screw System, which received clearance from the U.S. Food and ...
(Date:9/24/2018)... (PRWEB) , ... September 24, 2018 , ... ReGrow ... bring the highest quality and most affordable option for hair regrowth in the comfort ... to launch on October 2, 2018. , The sophisticated design and advanced technology ...
Breaking Biology Technology:
(Date:10/3/2018)... Ireland (PRWEB) , ... October ... ... biotechnology company focused on the discovery, development and commercialization of first-in-class stromal ... is being administered to patients with type 2 diabetes and progressive diabetic ...
(Date:10/2/2018)... ... October 02, 2018 , ... Through this webinar, sponsored ... FLIPR screening. They will also learn the role of calcium kinetics in cardiac safety ... chief operations officer at PPSC Biography; and Tsang Wai Lam, an assay development scientist ...
(Date:10/1/2018)... ... October 01, 2018 , ... ... conjugate (ADC) like, lipid based therapeutics, today announced the National Institute of ... the award of first year funding for two separate grants. These two grants ...
Breaking Biology News(10 mins):